Hit the 40 billion market!

A few days ago, Henan Tianfang Pharmaceutical Traditional Chinese Medicine/Shenzhen Shasong Lesheng received the CDE acceptance for the marketing application of Naoshang Lesheng Granules submitted in the new drug category 1.
1.
This is the first class 1 new cerebrovascular Chinese patent medicine to be produced in China
.
According to data from Meinenet, the market size of Chinese patent medicines for cerebrovascular diseases in China's public medical institutions and physical pharmacies in cities in China will exceed 40 billion yuan in 2020
.
Source: CDE official website Naoshang Lesheng Granule is a new Chinese medicine developed by Henan Tianfang Pharmaceutical Co.
, Ltd.
and Shenzhen Shasong Lesheng.
It has the effects of nourishing qi and blood, invigorating the brain, and removing blood stasis and dredging collaterals.
It is suitable for the treatment of traumatic brain injury and After craniocerebral surgery, the symptoms such as weakness of Qi and blood, damage to the brain and veins, stasis and meridian paralysis
.
Henan Tianfang Pharmaceutical TCM once submitted a listing application for Naoshang Lesheng Granules (new drug category 6.
1) to the State Food and Drug Administration in 2013, and voluntarily withdrew it in 2016.
After five years, it resubmitted the listing application with a new drug category 1.
1
.
According to Meinenet data, in 2020, the market size of Chinese city public hospitals, county-level public hospitals, urban community centers, township health centers (Chinese public medical institutions) and Chinese urban physical pharmacies terminal cerebrovascular disease Chinese patent medicines will exceed 40 billion yuan.
The terminal of public medical institutions in China is the “main battlefield” of Chinese patent medicines for cerebrovascular diseases, but the market scale of this sub-category of products in the terminal of physical pharmacies in Chinese cities has been significantly expanded
.
Sales of proprietary Chinese medicines for cerebrovascular diseases in physical pharmacies in cities in China (unit: 10,000 yuan) Source: Mi Nei.
com Competitive pattern of terminal cerebrovascular diseases in physical pharmacies in cities in China In recent years, the market scale of Chinese patent cerebrovascular diseases in physical pharmacies in cities has expanded and increased year by year The speed is also increasing year by year, and the overall sales scale is expected to exceed 6 billion yuan in 2021, a year-on-year increase of about 17%
.
2021E Chinese city physical pharmacy terminal cerebrovascular disease Chinese patent medicine TOP5 product source: Menet.
com Chinese city physical pharmacy terminal competition pattern 2021E Chinese city physical pharmacy terminal cerebrovascular disease Chinese patent medicine TOP5 product total market share reaches 75%, of which Angong Niuhuang Wan dominates "Half of the country", sales are far ahead of other products
.
Source: Mi Nei.
com database, CDE official website, etc.
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the city that covers 293 prefectures and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors the entire category Physical pharmacy database
.
The above sales are calculated based on the average retail price of the product at the terminal!